Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Roche Holding Ltd. : UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Reminds Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 10:03pm CEST

IRVINE, CA / ACCESSWIRE / July 17, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Roche Holding AG ("Roche Holding" or the "Company") (OTCQX: RHHBY). Investors, who purchased or otherwise acquired shares from March 2, 2017 through June 5, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the August 7, 2017 lead plaintiff motion deadline.

If you purchased shares of Roche Holding during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose material information, specifically that the combination of the Company's breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher rate of side effects. Following this news, Roche Holding's stock price dropped materially, causing investors harm according to the Complaint.

If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]

SOURCE: Khang & Khang LLP


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
04/26Overshadowed by Takeda bid, Shire reports solid start to year
RE
04/26Biosimilar worries takes shine off Roche's guidance hike
RE
04/26Roche Lifts Outlook as 1Q Sales Rise Above Expectations -- Update
DJ
04/26Correction to Roche Article on 1Q Sales
DJ
04/26Roche Raises Outlook After 1Q Sales Increase
DJ
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
04/23ROCHE : New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions..
BU
04/18GSK flags pharma M&A ambitions by poaching Roche deal-maker
RE
04/18Shire faces criticism on CEO pay policy as crunch week looms
RE
04/17ROCHE : FDA Grants Breakthrough Therapy Designation for Genentech’s HEMLIB..
BU
More news
News from SeekingAlpha
04/26BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Takeda Raises Shire Bid, Daiichi Fails DM.. 
04/26Roche Holding Ltd ADR 2018 Q1 - Results - Earnings Call Slides 
04/26Roche Holding ADR reports Q1 results 
04/26Roche Q1 sales up 5%, core earnings growth expected to be high single-digit 
04/25BIOGEN : Down Too Far, Too Fast? 
Financials ( CHF)
Sales 2018 55 182 M
EBIT 2018 18 555 M
Net income 2018 11 868 M
Debt 2018 4 203 M
Yield 2018 3,97%
P/E ratio 2018 15,26
P/E ratio 2019 14,54
EV / Sales 2018 3,53x
EV / Sales 2019 3,34x
Capitalization 191 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 258  CHF
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-11.66%193 904
JOHNSON & JOHNSON-9.68%338 522
PFIZER2.32%220 455
NOVARTIS-8.69%202 567
MERCK AND COMPANY5.97%161 967
AMGEN-1.13%114 902